Renal cell carcinoma (RCC) occurs in 2% to 4% of patients with tuberous sclerosis complex (TSC). Previous reports have noted a variety of histologic appearances in these cancers, but the full spectrum of morphologic and molecular features has not been fully elucidated. We encountered 46 renal epithelial neoplasms from 19 TSC patients and analyzed their clinical, pathologic, and molecular features, enabling separation of these 46 tumors into 3 groups. The largest subset of tumors (n = 24) had a distinct morphologic, immunologic, and molecular profile, including prominent papillary architecture and uniformly deficient succinate dehydrogenase subunit B (SDHB) expression prompting the novel term "TSC-associated papillary RCC (PRCC)." The second group (n = 15) were morphologically similar to a hybrid oncocytic/chromophobe tumor (HOCT), whereas the last 7 renal epithelial neoplasms of group 3 remained unclassifiable. The TSC-associated PRCCs had prominent papillary architecture lined by clear cells with delicate eosinophilic cytoplasmic thread-like strands that occasionally appeared more prominent and aggregated to form eosinophilic globules. All 24 (100%) of these tumors were International Society of Urological Pathology (ISUP) nucleolar grade 2 or 3 with mostly basally located nuclei. Tumor cells from 17 of 24 TSC-associated PRCCs showed strong, diffuse labeling for carbonic anhydrase IX (100%), CK7 (94%), vimentin (88%), and CD10 (83%) and were uniformly negative for SDHB, TFE3, and AMACR. Gains of chromosomes 7 and 17 were found in 2 tumors, whereas chromosome 3p deletion and TFE3 translocations were not detected. In this study, we reported a sizable cohort of renal tumors seen in TSC and were able to identify them as different morphotypes, which may help to expand the morphologic spectrum of TSC-associated RCC.
T uberous sclerosis complex (TSC) is an autosomal dominant genetic disorder. Once characterized by epilepsy, developmental delay, and facial angiofibromas, the syndrome can affect nearly every organ system to varying degrees, including the brain, skin, heart, lungs, and kidneys. The incidence of TSC is estimated to be 1 in 6000 to 1 in 10,000 persons worldwide. 1 A disease-causing mutation in either TSC1 (chromosome 9q34), encoding the protein hamartin, or in TSC2 (chromosome 16p13), encoding the protein tuberin, can be identified in most patients with TSC. These proteins act together as tumor suppressors and are components of the mTOR (mammalian target of rapamycin) signaling pathway. 2 The kidney is affected in approximately 80% to 85% of individuals with TSC, and renal involvement has been reported as the leading cause of death in TSC patients. 1, 3 Renal manifestations in TSC include angiomyolipoma (AML), simple and complex cysts, and renal epithelial neoplasms, including oncocytoma and renal cell carcinoma (RCC). With the increasing awareness and surveillance, RCCs are more commonly reported, both in adults and children with TSC. An estimated incidence of RCC in TSC patients is reported to be 2% to 4%, higher than the estimated incidence in the general population, 4 and often occurs in children and young adults. 5, 6 A variety of histologies of TSC-associated RCCs have been reported, including clear cell, papillary, chromophobe, and unclassified RCC, as well as benign renal oncocytoma. 5, [7] [8] [9] [10] [11] However, the full spectrum of morphologic features has not yet been well elucidated because of limited amounts of pathologic material in some cases, and overlapping features with fat-poor AMLs. Furthermore, the immunophenotype of TSC-associated RCC has not been studied using modern antibody repertoires. 5, [11] [12] [13] Few RCCs in TSC patients have been reported to have coexpression of renal tubular and melanocytic markers such as HMB45 and unlikely represented Xp11 translocation RCC, which further added to the tumor heterogeneity identified in these patients. 5, 14 Absence of von Hippel-Lindau (VHL) gene mutation and loss of heterozygosity were reported in 6 clear cell TSC-associated RCCs, 13 in contrast to cytogenetic findings in sporadic RCC of the general non-TSC population, suggesting that clear cell TSC-associated RCC develops independently of canonical pathways.
To better understand and characterize TSC-associated RCCs, we have studied 46 renal epithelial tumors from 19 TSC patients. We performed immunohistochemical and cytogenetic analysis and described the morphologic findings among this group of tumors. We sought to investigate whether any particular histologic type of renal cell neoplasm was more frequently found in TSC and whether any distinct histologic features correlated with genetic abnormalities and/or immunoprofiles. We found that a sizeable subset of TSC-associated renal tumors in this series, 39 of 46 (85%), seen in 17 of 19 (90%) TSC patients, had distinct features as described below.
MATERIALS AND METHODS

Patient and Tumor Specimens
All 19 patients were treated at the authors' institutions with a clinical diagnosis of TSC as defined by the 1998 Tuberous Sclerosis Complex Consensus Conference. 15, 16 Tumors were provided by the Massachusetts General Hospital, Boston, MA (n = 9), Brigham and Women's Hospital, Boston, MA (n = 5), University of Massachusetts Medical School, Worcester, MA (n = 1), University of Michigan Health System, Ann Arbor, MI (n = 1), University of California, San Francisco, CA (n = 1), Children's Memorial Hospital, Warsaw, Poland (n = 1), and Peking Union Medical College Hospital, Beijing, China (n = 1). The original pathologists varied in their interpretation of the histologic findings: 1 was considered to be oncocytoma, 3 were considered to be papillary RCC (PRCC) (1 type 1 and 2 type 2), 5 were considered to be clear cell RCC, 5 were considered to be chromophobe RCC, and 32 were considered to be RCC, unclassified.
The patient demographics, clinical history, and follow-up details were obtained from clinical records. This study was approved by the human study committees at each hospital. The gross findings, including the number and size of the tumors, and laterality, were noted from the pathology reports. All 46 tumors assessed here were formalin fixed and paraffin embedded (FFPE). Sections of each tumor of 4 mm thickness with accessible tissue were obtained for hematoxylin and eosin stain, immunohistochemistry, and fluorescence in situ hybridization (FISH) analyses. Histologic subtypes of RCCs were reviewed and reclassified according to criteria proposed in the 2004 World Health Organization (WHO) classification of neoplasms of the kidney and International Society of Urological Pathology Vancouver Classification of Renal Neoplasia 17 and evaluated for the International Society of Urological Pathology (ISUP) nucleolar grade. 18 The tumors that morphologically did not fit the criteria for the usual common renal cell neoplasms were initially assigned the designation of unclassified RCC, according to the above-mentioned classification system. Attempts were made later to group such tumors into more definitive categories if any consistent morphologic and/or immunohistochemical features were observed.
Immunohistochemistry
At least 1 FFPE tissue block from each available tumor was selected for immunohistochemical analysis. Multiple markers beneficial in discriminating different subtypes of RCC were used: CK7 (Dako, Carpinteria, CA; clone OV-TL 12/30; 1:3 dilution); carbonic anhydrase IX (CA-IX) (Novus Biologicals, Littleton, CO; Clone 2D3; 1:5000 dilution); CD10 (Leica, Buffalo Grove, IL; clone 56C6; prediluted); AMACR/P504S (Dako; Clone 13H4; 1:300 dilution); RCC Ma (Dako; clone 5PM314; 1:50 dilution); CD117 (Cell Marque, Rocklin, CA; clone YR145; prediluted); PAX8 (Cell Marque; rabbit polyclonal; 1:50 dilution); HMB45 (Leica; clone HMB45; prediluted); vimentin (Leica; clone SRL33; prediluted); succinate dehydrogenase subunit B (SDHB) (Abcam Inc., Cambridge, MA; clone 21A11AE7; 1:1000 dilution), TFE3 (Cell Marque; clone MRQ-37; prediluted).
Immunohistochemical analysis was performed using the Leica Bond platform (Leica). Sections were deparaffinized on the automated stainer using Bond Dewax Solution (Leica) and rehydrated through graded ethanol solutions to distilled water. Antigen retrieval was achieved by heating sections in citrate-based solution (pH 6.0, Leica) for CK7, CA-IX, and HMB45, or EDTAbased solution (pH 9.0, Leica) for TFE3, AMACR, CD10, vimentin, CD117, PAX8, and SDHB. Bound antibodies were localized using Polymer Refine Kit (Leica) or Ultra Vision LP Detection System HRP Polymer (Thermo Scientific, Fremont, CA). Diaminobenzidine (3,3 0 -diaminobenzidine) was used as the chromogen, and hematoxylin was used as a counterstain. Positive and negative controls were stained concurrently and showed appropriate immunostaining.
The extent of immunohistochemical staining was evaluated microscopically. The percentage of tumor cells showing a positive reaction was estimated, and, when appropriate, the staining pattern was documented (membranous, cytoplasmic, apical, granular cytoplasmic, etc.). The interpretation of immunoreactivity for TFE3 and SDHB were evaluated as previously described. [19] [20] [21] [22] SDHB stain was considered negative when all tumor cells showed diffuse negative staining compared with the adjacent, normal renal tubular cells showing strong positive staining. SDHB immunohistochemistry was applied on tumors with multiple blocks to confirm the negative results presented in the representative section. SDHB immunohistochemistry was repeated when tumor cells showed negative labeling in the absence of adjacent normal kidney parenchyma (internal positive control). SDHB immunohistochemical analysis was also performed on a limited number of cases of clear cell, papillary, and chromophobe RCCs under the same conditions, which were used as positive controls. Other stains were graded as negative (0% cells positive), À /+ (1% to 25%),+ (26% to 50%), ++ (51% to 75%), +++ (76% to 100%).
Hale Staining
Hale colloidal iron staining (Muller-Mowry modification) was performed in all HOTC cases. The staining pattern was evaluated as negative, diffuse cytoplasmic, or apical.
Fluorescence In Situ Hybridization
For patients with available tissue, at least 1 FFPE tissue block was selected for FISH.
FISH analyses were performed as described previously. [22] [23] [24] Briefly, a hematoxylin and eosin-stained slide from each block was examined to identify areas containing tumor cell clusters for cell counting. Multiple tissue sections 4 mm in thickness were prepared from FFPE tissue blocks. The slides were deparaffinized with 2 washes of xylene, 15 minutes each, and subsequently washed twice with absolute ethanol, 10 minutes each, and then air dried in a fume hood. Next, the slides were treated with 0.1 mM citric acid (pH 6.0) (Zymed, South San Francisco, CA) at 951C for 10 minutes, rinsed in distilled water for 3 minutes, followed by a wash of 2 Â standard saline citrate (SSC) for 5 minutes. Digestion of the tissue was performed by applying 0.4 mL of pepsin (5 mg/mL in 0.1 N HCl/0.9 NaCl) (Sigma, St Louis, MO) at 371C for 40 minutes. The slides were rinsed with distilled water for 3 minutes, washed with 2 Â SSC for 5 minutes, and air dried.
Centromeric chromosome enumeration probes (CEP) were utilized for chromosome 3 (CEP3, Orange), chromosome 7 (CEP7, Green), and chromosome 17 (CEP17, Orange) from Vysis (Downers Grove, IL). FISH for chromosomes 7 and 17 was performed with centromeric a-satellite DNA probe cocktail containing CEP7 and CEP17. Deletion of chromosome 3p was assessed using a probe cocktail containing centromeric a-satellite DNA probes for CEP3 (Spectrum Orange) and the subtelomeric probe for 3p25 (3pTel25, Spectrum Green; Vysis). Assessment of TFE3 translocation was done using an Interphase Break-apart FISH assay with the 2 DNA probes. 22 Probes CEP7-CEP17 were diluted with tDen-Hyb1 in a ratio of 1:100, and probes CEP3-3p25, TFE were diluted with tDenHyb 2 (Insitus, Albuquerque, NM) in a ratio of 1:100 and 1:25, respectively. The diluted probe (5 mL) was applied to each slide under reduced light conditions. The slides were then covered with a 22 Â 22mm cover slip and sealed with rubber cement. Denaturation was achieved by incubating the slides at 831C for 12 minutes in a humidified box and hybridization at 371C overnight. The cover slips were removed, and the slides were washed twice with 0.1 Â SSC/1.5 M urea at 451C (20 min for each), followed by a wash with 2 Â SSC for 20 minutes, and with 2 Â SSC/0.1% NP-40 for 10 minutes at 451C. The slides were further washed with 2 Â SSC at room temperature for 5 minutes. The slides were air dried and counterstained with 10 mL 4,6-diamidino-2-phenylindole (Insitus), covered with cover slips and sealed with nail polish.
FISH Evaluation
The slides were examined using a Zeiss Axioplan 2 microscope (Zeiss, Gottingen, Germany) with the following filters (Chroma, Brattleboro, VT): SP-100 for DAPI, FITC MF-101 for Spectrum Green and Gold 31003 for Spectrum Orange. The images were acquired with a charged coupled device camera and analyzed with MetaSystem Isis Software (MetaSystem, Belmont, MA). Four sequential focus stacks with 0.4 mm intervals were acquired and then integrated into a single image to reduce thickness-related artifacts.
The method of analysis was partially described previously. 22, 25 In brief, for each slide, a minimum of 100 tumor cell nuclei were examined under fluorescence microscopy at Â 1000 magnification. Only nonoverlapping tumor nuclei were evaluated. Non-neoplastic renal cortex was examined as an internal control. Definitions of chromosomal trisomy of chromosomes 7 and 17 were based on the Gausian model and were related to the nonneoplastic controls. The cutoff values for each probe were set at mean+3 SDs of the control values. 26, 27 The cutoff value for 3p deletion was defined as a 3p25/CEP3 ratio of r0.7, as previously described. 24, 28, 29 A TFE3 fusion result was reported when Z10% of the tumor nuclei showed the split-signal pattern, on the basis of other commercially available break-apart FISH assays and TFE3 break-apart FISH assays. 30 
RESULTS
The clinicopathologic characteristics of 46 TSC-associated RCCs are summarized in Table 1 . There was a predominance of female patients (male to female ratio 1:2). Mean age at the first diagnosis of a renal tumor was 30 years (range from 7 to 59 y). Three patients underwent biopsy, 2 chose conservative management, and 1 declined surgical intervention and has since died. Four patients underwent radical nephrectomy, and 12 had partial nephrectomy. Follow-up data were available for 14 of 19 (74%) patients with a mean follow-up period of 48 months (range from 3 to 147 mo). One patient had regional lymph node metastasis at presentation (patient 6); she has remained free of distant metastasis but has since developed new bilateral renal neoplasms in her most recent surveillance imaging. All other treated patients are alive with neither recurrence nor metastasis.
The average tumor size was 2.9 cm (range, 0.1 to 22 cm). Forty-eight percent of the tumors were ISUP grade 2, whereas ISUP grades 1, 3, and 4 were 6%, 44%, and 2%, respectively. Eight of the 19 patients (42%) had multiple renal tumors (2 to 15), and 5 of 19 patients (26%) had bilateral neoplasms. Of 5 patients with bilateral tumors, 2 had synchronous bilateral lesions, and 3 had their contralateral tumor(s) diagnosed 1, 5, and 11 years after the initial nephrectomies. Concurrent, multiple renal AMLs, microscopic or macroscopic, were found adjacent to the tumors in 56% of patients, and cystic changes were observed in 56% of tumors.
The gross tumor appearance from 14 of 17 patients by partial or radical nephrectomy was noted to be well circumscribed and occasionally cystic. Eight tumors were described as encapsulated. The cut surface varied and was described as yellow, tan, red-brown, hemorrhagic, or variegated. No gross tumor necrosis was reported.
The combined morphologic, immunohistochemical, and cytogenetic approaches allowed us to subclassify these 46 tumors into 3 groups. The largest subset of tumors comprised 24 neoplasms and was termed TSC-associated PRCC. The second group contained 15 renal tumors morphologically similar to a hybrid oncocytic/ chromophobe tumor (HOCT). The last group of 7 renal epithelial neoplasms remained unclassifiable ( Table 2 ).
TSC-associated PRCC
Ninety-one percent of 24 group 1 tumors were microscopically circumscribed by fibrous stroma of variable thickness. On low power, a complex branching papillary architecture was observed in 75% of the tumors (18/24) (Figs. 1A, C, 2A). In the remaining 6 tumors, papillary architecture was present focally, appearing as small blunt papillae tufting into the lumen (Fig. 4E ). One of these tumors (patient 7, tumor 12) exhibited an overwhelmingly nested growth pattern (Figs. 4A-C), whereas 5 others, all from patient 8, showed a primarily solid growth pattern (Figs. 4D-F). Patient 8 had 10 additional predominantly papillary tumors, similar to those displayed in Figures 1 and 2. These 15 tumors from patient 8 showed several growth patterns (solid, compact nested or papillary) that merged with each other (Figs. 4D-E). Cystic change was commonly present (13/24), usually as microcysts (Fig. 1E ). The cells lining the cysts were morphologically similar to those in the rest of the tumor. Other architectural patterns, including acinar, tubular, and alveolar patterns, were observed in varying proportions.
Cytologically, all except 1 tumor were predominantly composed of large clear cells with voluminous cytoplasm. Cells with finely granular, eosinophilic cytoplasm were focally present in 14 of 24 tumors. Tumor cells with clear cytoplasm were admixed with tumor cells with eosinophilic cytoplasm without forming large geographic aggregates of one cell type ( Fig. 1F ). On high power, the clear cytoplasm often contained delicate thread-like eosinophilic strands that occasionally All tumor parenchyma were surrounded by hyalinized stroma, which sometimes showed myxoid change (Figs. 1E, 2A, 4D) . Focal hemorrhage and necrosis occurred in 1 tumor removed shortly after embolization treatment (patient 7, tumor 12).
Only patient 6 had pathologically confirmed metastasis to 3 of 8 peri-aortic lymph nodes (the largest metastatic node was 1.3 cm) that were resected synchronously with the kidney tumor. The morphologic features of the nodal metastasis resembled the kidney tumor.
Seventeen of 24 group 1 renal tumors had adequate tissue for immunohistochemical analyses. Results of immunohistochemistry evaluation are displayed in Table 3 . SDHB protein expression was absent in all 17 tumors studied (Figs. 2F, 3A-F, 4I). Negative SDHB labeling was interpreted only when the tumor cells showed diffuse negative staining, and the adjacent normal renal tubular cells showed positive granular cytoplasmic staining. CK7 expression was strongly and diffusely positive in almost all tumors (17/18) (Figs. 2C, 4G) , and all CK7-expressing tumors exhibited predominantly papillary growth. The only tumor (tumor 12) showing focal CK7 expression (5%) was composed of nested clear to eosinophilic cells with rare papillary structures (Figs. 4A-C). Unlike sporadic PRCC, these TSC-associated tumors completely lacked staining for AMACR. CA-IX membranous staining was diffusely positive in all tumors, resembling clear cell RCC (Figs. 2D,  4H ). CD10 staining was positive in all cases, mostly strong, and diffuse ( Fig. 2E) , although weak and/or focal positivity for CD10 was seen in 3 tumors displaying a primarily solid growth (patient 8). Vimentin and PAX8 were consistently positive in a majority of tumors (15/17 and 15/15, respectively). All tumors studied were negative for TFE3, HMB45, RCC Marker, and CD117. In summary, tumors within this group showed an immunoprofile distinctly different from any existing renal neoplasm subtype, which is summarized as: SDHB À / TFE3 À /RCC Ma À /vimentin ++ /CK7 ++ /AMACR À / CA-IX ++ /CD10 ++ .
FFPE blocks from 16 of these group 1 tumors were sectioned and analyzed by FISH, as summarized in Table 3 . None of the 16 tumors showed evidence of chromosome 3p deletion. Two neoplasms (tumor 12 and 28) showed gains of chromosomes 7 and 17. None of the tumors showed evidence of a TFE3 gene fusion by break-apart FISH assay.
Hybrid Oncocytic/Chromophobe Tumor
Fifteen of the 46 (33%) renal epithelial neoplasms displayed morphologic characteristics of both an oncocytoma and chromophobe RCC, albeit in varying amounts, similar to an HOCT. There were 2 main histologic patterns identified in these neoplasms. The first pattern, displayed in 5 of 15 (33%) HOCT tumors, were comprised of polygonal tumor cells with abundant eosinophilic cytoplasm and centrally placed, round nuclei, resembling an oncocytoma, with perinuclear cytoplasmic clearing or halos, similar to chromophobe RCC (tumors À /+ indicates 1% to 25% positive; +, 26% to 50% positive; ++, 51% to 75% positive; +++, 76% to 100% positive; N, negative result recorded on pathologic report; NA, not available; Neg, negative; P, positive result recorded on pathologic report. 7, 9, 36, 42, 45) (Figs. 5A, B) . The second contained a mosaic pattern, identified in 5 of 15 (33%) HOCT tumors, in which there was admixing of areas with features characteristic of oncocytoma and chromophobe RCC (tumors 29, 30, 35, 43, 44) (Fig. 5C ). The 5 remaining tumors that did not exhibit either of the 2 predominant histologic patterns demonstrated various combinations of morphologic features of the 2 neoplasms. Four of the 5 tumors contained a nested and tubular architecture with cells comprising abundant eosinophilic cytoplasm typical of an oncocytoma with more irregular, folded, or raisinoid nuclei, a quality of chromophobe RCC (Fig. 5D ) (tumors 1, 37, 39, 41, 46) .
The immunoprofile and FISH results of the tumors from this group are reported in Table 3 . In general, the tumors were reactive for PAX8, CD117, and CD10 and negative for TFE3, HMB45, and CA-IX. Immunostaining with vimentin, RCC, and AMACR was variable. All of the tumors had preserved SDHB immunoreactivity. None of the tumors revealed aberrations in chromosomes 3p, 7, or 17. In addition, a TFE3 translocation was not observed in any of the tumors. 
Unclassified RCC
A small subset of RCCs (n = 7) contained morphologic and/or architectural patterns that did not readily fit into any of the WHO classification of RCC subtypes. Therefore, they were categorized as unclassified RCCs (Fig. 6 ).
Tumors 4, 5, and 6 from patient 4 displayed a variety of morphologies. Tumor 4 contained tubules and papillae lined by cells with abundant eosinophilic cytoplasm with centrally placed round nuclei and prominent nucleoli intermixed with moderate amounts of inflammatory infiltrate (Fig. 6A ). Immunohistochemically, it was positive for vimentin, RCC Ma, CD10, and AMACR and negative for CK7, CA-IX, and CD117. Tumor 5 contained a papillary architecture lined by a single layer of cuboidal cells with clear to eosinophilic cytoplasm and small round nuclei (Fig. 6B) . Immunohistochemically it was positive for vimentin, RCC Ma, CK7, and AMACR and negative for CD10, CA-IX, and CD117. Tumor 6 contained a papillary architecture lined by both clear to eosinophilic cytoplasm and round nuclei (Fig. 6C) with an immunoprofile that was positive for vimentin, RCC Ma, and AMACR and negative for CK7, CD10, CA-IX, and CD117.
Both tumors 32 (Fig. 6E ) and 34 (Fig. 6F ) from patient 11 were well circumscribed and composed of cuboidal cells with densely eosinophilic cytoplasm and oval to mildly irregular nuclei. The neoplastic cells were arranged in either compact nests or small tubules. Foamy macrophages were commonly seen in the lumen of the tubules or within the stroma. The immunoprofiles of these 2 tumors were: vimentin À /RCC À /CK7 À /CD10 + /CA-IX À /AMACR ++ /PAX8 À .
Tumor 33 (Fig. 6D ) also from patient 11 was well circumscribed and composed of sheets of cells with fluffy , showing the compact nested architecture consisting of clear cells with fine eosinophilic thread-like strands. D, Solid cell nests were surrounded by loose hyalinized stroma. E, Tubules with small blunt papillae tufted into the luminal space. F, On high power, clear cells with eosinophilic strands formed compact nests. G-I, Immunohistochemical stains showed that tumor cells were strongly and diffusely positive for CK7 and CA-IX and negative for SDHB. eosinophilic cytoplasm and small uniform nuclei with inconspicuous nucleoli. The tumor cells only showed diffuse positive immunoreactivity for CA-IX and were negative for all the other markers in the immunohistochemical panel.
Tumor 40 (Figs. 6G-I) from patient 17 was composed of cuboidal cells with indistinct cell borders, arranged in compact nests and separated by abundant sinusoidal vasculature. The cytoplasm was oncocytic with a granular and vacuolated quality. Nuclei were centrally placed, round to oval in shape, and displayed finely granular chromatin and small nucleoli. The immunohistochemical profiles and morphologic features of these neoplasms did not readily fit into any of the WHO RCC classifications.
Material was available for immunohistochemistry from 7 and FISH from 6 of the tumors in this group. Results are summarized in Table 3 . In brief, all tumors were negative for TFE3 and HMB45. Preservation of SDHB by immunohistochemistry was also present.
Immunohistochemical staining for the other markers showed variable patterns. There were no aberrations identified in chromosomes 3p, 7, or 17. In addition, no TFE3 gene fusions were detected.
DISCUSSION
Whereas most RCCs occur sporadically, 3% to 5% are associated with hereditary syndromes. To date, there are 10 well-defined hereditary renal cancer syndromes, including VHL disease, hereditary PRCC, hereditary leiomyomatosis-RCC, Birt-Hogg-Dube´(BHD) syndrome, and TSC, among others. 31 Homogenous tumors are seen in some RCC syndromes, such as clear cell RCC in VHL disease and type 1 PRCC in hereditary PRCC. Heterogenous tumors are reported in BHD syndrome.
RCC is a rare renal manifestation in TSC patients, with an estimated incidence of 2% to 4%, which is nonetheless higher than in the general population. 4 Although renal carcinomas have been increasingly found in TSC patients, their histologic and molecular characteristics remained poorly defined. The reported histologic appearance of TSC-associated RCCs is heterogenous. Most have been identified as clear cell RCCs, but other reported types include papillary, chromophobe, and unclassified RCC as well as benign renal oncocytoma. 5, [7] [8] [9] [10] [11] In this study, we first describe 24 renal epithelial neoplasms from 9 TSC patients for their morphologic, immunophenotypic, and cytogenetic features. Morphologically, these tumors displayed a prominent papillary architecture lined predominantly by cells with clear cytoplasm. Prominent complex, branching papillary structures are a hallmark of these tumors. Another unique feature is the delicate eosinophilic cytoplasmic thread-like strands, not seen in other types of RCC. Immunologically, all studied neoplasms were consistently positive for CK7, vimentin, CD10, and CA-IX, with no immunoreactivity for SDHB, TFE3, AMACR, and RCC Marker. This immunologic profile is distinct from all other known RCC subtypes.
Each of the 4 known RCC subtypes-clear cell RCC, type 1 PRCC, Xp11 translocation RCC, clear cell (tubulo) PRCC (CCPRCC)-share some morphologic and immunologic features with the TSC-associated PRCC ( Table 4) .
For example, all the TSC-associated PRCCs consistently displayed reactivity to vimentin, CD10, PAX8, and CA-IX and were negative for AMACR, which is a typical immunohistochemical profile of clear cell RCC. But the TSC-associated tumors were also diffusely and strongly positive for CK7 and uniformly negative for SDHB, distinguishing them from clear cell RCC. In addition, the diffuse membranous staining for CA-IX among these tumors, presumably reflecting activation of the hypoxia-inducible factor (HIF) pathway, was similar to sporadic clear cell RCC; however, no deletion of chromosome 3p, in which the VHL gene resides, was detected in any neoplasm examined. Duffy et al 13 similarly found neither VHL loss of heterozygosity nor other VHL gene mutations in any of their 6 clear cell RCC tumors from TSC patients. Together these findings indicate that this novel tumor subset is distinct from sporadic clear cell RCC and may implicate a novel mechanism to activate the HIF pathway in renal cell carcinogenesis in the setting of TSC. Xp11 translocation RCC is another renal tumor in the differential diagnosis. This neoplasm is typically composed of cells with voluminous clear to faintly eosinophilic cytoplasm, arranged in papillary and nested structures. Nuclear labeling for TFE3 protein by immunohistochemistry is a characteristic feature of Xp11 translocation carcinoma and was not identified in any of the neoplasms in our series. This observation was further validated by break-apart TFE3 FISH assay, which showed no TFE3 gene translocation in these tumors. 32 In contrary to the high nuclear grade in Xp11 translocation RCC, most tumors in our series were intermediate nuclear grade. Psammoma bodies that are common in Xp11 translocation RCC were also not seen in any of these TSC-associated tumors.
A recently emerged entity, CCPRCC, is recognized and classified within the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. 17 One of the characteristic features of CCPRCC is the apical positioning of the low-grade nuclei away from the basement membrane, arranged in a linear manner, which was only focally present in 2 tumors in our study. The CCPRCC-specific cup-shaped expression pattern of CA-IX was not identified in any of our samples. Instead, CA-IX was diffusely and circumferentially expressed along the cell membrane in all tumors, resembling clear cell RCC. Furthermore, CD10 staining was diffusely positive in almost all tumors, different from its negative to variable staining in CCPRCC.
PRCC tumor cells contain a small amount of clear to slightly eosinophilic cytoplasm. The abundant clear cell cytoplasm seen in the TSC-associated PRCC tumors is uncommon in PRCC. Although clear cell changes and fine cytoplasmic granulations can be occasionally seen in PRCC, these changes usually appear adjacent to hemosiderin deposition and/or necrosis, associated with global degenerative changes. 33 Psammoma bodies and foamy histiocytes in the fibrovascular cores, common features in PRCC, were not seen in any of these TSC-associated tumors. Although TSC-associated PRCC tumors were positive for CK7, similar to PRCC, CA-IX was also diffusely and strongly positive, unlike typical PRCC, and AMACR expression was uniformly absent. Even though 2 tumors within this group showed gains of chromosomes 7 and 17, the typical immunohistochemical profile of PRCC (positive for both CK7 and AMACR) is not appreciated. The significance of gains of chromosomes 7 and 17 in these 2 tumors is not understood.
Another interesting finding in this study was that this subset of renal neoplasms uniformly lacks expression of SDHB protein by immunohistochemistry. Succinate dehydrogenase (SDH)/mitochondrial complex II is a key respiratory enzyme located in the inner mitochondrial membrane that links 2 important pathways in energy conversion: the Krebs tricarboxylic acid cycle and oxidative phosphorylation. It catalyzes the oxidation of succinate to fumarate and transfers electrons to the respiratory chain ubiquinone pool. 34 Five proteins are involved in the SDH complex, SDHA, SDHB, SDHC, SDHD, and SDHAF2, and are encoded by 5 nuclear genes, which together are known as SDHx genes/SDH complex genes. SDHA and SDHB form the catalytic core of the enzyme complex.
Inherited or somatic mutations in SDHx genes are well documented and associated with the development of pheochromocytoma/paraganglioma (PHEO/PGL) and, less commonly, with gastrointestinal stromal tumors. Thus, SDHx genes are regarded as tumor suppressors. RCCs have rarely been reported with germline mutations in SDHB, 19, [35] [36] [37] [38] [39] [40] SDHC, 41 or SDHD. 38 Together, <20 patients with any SDHx gene mutation have been reported thus far and mostly with a personal and/or family history of PHEO/PGL. Double-hit inactivation of any component of the SDH complex results in degradation of the SDHB subunit. Therefore, immunohistochemistry for SDHB is negative whenever there is mutation/inactivation of SDHA, SDHB, SDHC, SDHD, or SDHAF2. Negative staining for SDHB has been quite reliable in identifying germline mutation of the SDH B, C, and D subunits in PHEO/PGL. 42, 43 In a few paraganglioma syndromeassociated renal tumors, negative SDHB expression was highly correlated with germline mutations in SDHB and SDHD genes. Notably, none of the TSC patients in our cohort has a personal or family medical history of PHEO/ PGL. The absence of a family history does not formally exclude the possibility of paraganglioma syndromes given the age-related penetrance of SDHx gene mutation and phenotypic heterogeneity. Nonetheless, our patients all met diagnostic criteria for TSC and had no features otherwise suggestive of the paraganglioma syndrome.
Renal tumors associated with SDHx mutations from earlier reports were classified as clear cell, chromophobe, papillary, and unclassified RCC, or oncocytoma, without detailed description or illustration of morphologic features. [35] [36] [37] [38] 44 More recent reports have emphasized the presence of distinctive cytoplasmic inclusions in cuboidal cells with bubbly eosinophilic cytoplasm arranged in solid nests. 17, 19, 40, 45 Importantly, we did not observe these features in any of the SDHB-negative renal tumors reported here. It remains to be determined whether the morphologic features of the renal tumors seen in these TSC patients are seen only in TSC or whether they will be also observed in non-TSC patients.
It is known that lack of SDH enzyme activity results in abnormal hypoxia signaling and may trigger tumor formation. Succinate accumulates as a result of SDH dysfunction, which consequently inhibits HIF-a prolyl hydroxylases in the cytosol, leading to stabilization and activation of HIF-1a. HIF-1a induction may then in turn upregulate multiple downstream genes including CA-IX. This effect may contribute to carcinogenesis in these tumors in the absence of VHL mutation or chromosome 3p loss and explains the diffuse membranous IHC labeling for CA-IX we observed. The mechanism of loss of SDH expression in these tumors is unknown. SDHx germline mutation seems quite unlikely, as these patients had no features of SDH genetic syndromes, and the coexistence of TSC1 or TSC2 plus SDHx germline gene mutations would be an extremely rare event to recur in this clustered manner by random chance. One possible mechanism may be the acquisition of somatic mutations that inactivate 1 or more of the SDHx genes, hence contributing to tumorigenesis. An alternative possibility is that the effects of TSC1/ TSC2 loss and mTORC1 activation in the particular renal epithelial cell of origin for these tumors may somehow interrupt normal SDH expression. It will be of interest to see whether similar cases are found in sporadic, non-TSC patients and to examine the molecular pathology of such cases for TSC and SDH gene involvement. If germline SDHx mutation is found in this group of tumors, it poses a possibility that 2 tumor-suppressor genes (SDH and TSC) may together contribute to 1 oncogenic event.
In this study, we additionally describe a second distinct morphologic group comprising 15 renal epithelial neoplasms from 9 TSC patients, which have features of an HOCT. HOCT tumors are most commonly described in patients with BHD syndrome and renal oncocytosis, with more recent reports of sporadic cases. [46] [47] [48] [49] [50] It is hypothesized that renal oncocytoma and chromophobe RCC are the extremes of the same morphologic spectrum, as they both originate from the intercalated cells of the renal collecting tubules, giving rise to neoplasms with mixed histology. 46 Although this subset of renal epithelial neoplasms does not have a distinct immunoprofile, their characteristic features may alert the pathologist to the possibility of a TSC-associated renal neoplasm, in addition to those associated with BHD syndrome. Furthermore, correctly diagnosing this neoplasm is important, as HOCTs have been identified as a subtype of chromophobe RCC by the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. 17 Interestingly, renal tumors with HOCT morphology are identified in both TSC and BHD syndromes in which mutations in the TSC and folliculin genes, respectively, result in downstream mTOR activation. Therefore, we hypothesize that the tumors associated with these hereditary syndromes may acquire a similar or shared somatic mutation or genetic alteration, resulting in their distinct morphology. Further studies using modalities such as genome sequencing may help elucidate the morphologic link between these 2 hereditary syndromes.
In conclusion, RCCs in TSC contain distinct morphologic features and include TSC-associated PRCC and HOCT. Similar to other well-defined hereditary renal cancer syndromes in which distinct RCC morphologic features are associated with specific mutations, these neoplasms, in addition to AMLs, may help identify morphologic clues to renal neoplasms associated with TSC.
